iosr-JPBS   Volume-11 ~ Issue-5 ~ Sep-Oct 2016

[1]. Nyol Sandeep, Dr. M.M. Gupta. Immediate Drug Release Dosage Form: A Review. J Drug Delivery & Therapeutics 2013; 3(2): 155-161.
[2]. Utsav Patel, Khushbu Patel, Darshan Shah, Rushabh Shah. A Review on Immediate Release Drug Delivery System. Int J Pharma Res and Biosci 2012; (5): 37-66.
[3]. Dedhiya: Lercanidipine Immediate Release Compositions United States Patent Application 20060134212.
[4]. R. Natarajan, Rohit Vaishnani,and NN. Rajendran, Formulation and Evaluation of Immediate Release Tablets of Paroxetine HCl Using Different Superdisintegrants, IJRPBS Sep 2011; 2(3): 1095-1099.
[5]. Srinivas Pannala, Mahalaxmi Rathnanand,Preparation and in vitroEvaluation of Nizatidine immediate release tablets, International Journal of PharmTech Research 2011; 3(3): 1688-1692.

[1]. AKK Marry, YY Lloyd, KA Brian, LC Robin, AK, Wayne Applied therapeutics the clinical use of drug. WoltersKlawer / Lippincott Williams and Wilkins(9,2009;9:53-1)
[2]. F Dajas, Rivera, FMegret, F Blasina. Neuroprotective by Flavonoids. Brazil J Med Biol Res, 36,2003,1613-1620.
[3]. EJ Lee, HY Chen, IA Ayoub, KI Maynard, Acute administration of Ginkgo biloba extract (Egb 761) affords neuroprotection against permanent and transient focal cerebral ischemia in Sprague-Dawley rat. J Neurosci,68,2002,636-645.
[4]. ZA Shah, RA Gilani, P Sharma, SB Vohora. Cerebroprotective effect of Korean ginseng tea against global and focal models of ischemia in rat. J Ethnopharmacol,101,2005,299-307.
[5]. Nehlig,The neuroprotective effects of cocoa flavanol and its influence on cognitive performance, British Journal of Clinical Pharmacology, 75(3), 2013,716–727.

[1]. L.D. Fairclaugh, Design and Analysis of Quality of Life Studies in Clinical Trials (Charman & Hall, CRC, 2002).
[2]. P. Kind, A. Williams, Measuring success in health care – the time has come to do it properly, Health Policy Matter, 9, 2004, 1–8.
[3]. O.Kryvoviaz, Antiglaucoma pharmacotherapy: analysis of treatment regimens and efficacy indicators, ScienceRise,. 3/4 (20), 2016, 46–50.
[4]. O.V. Makarenko, O.V. Kryvoviaz, Iu.O. Tomashevska, Vplyv dopomizhnykh rechovyn v protyhlaukomnykh ochnykh krapliakh na pokaznyk yakosti zhyttia za kryteriiem chastoty pobichnykh efektiv, Farmatsevtychnyi zhurnal, 3, 2015, 39–44.
[5]. O. V. Makarenko. E. V. Krivovyaz, Otsenka kachestva zhizni bolnykh pervichnoy otkrytougolnoy glaukomoy, Materialy nauchnoy konferentsii «Sovremennaya farmatsevtika: teoriya. praktika. eksperimenty», Moskow, RF, 2014, 48–53.s

[1]. Regnault, A., Viala-Danten, M., Gilet, H. and Berdeaux, G. Scoring and psychometric properties of the eye drop satisfaction questionnaire (EDSQ), an instrument to assess satisfaction and compliance with glaucoma treatment. BMC Ophthalmol.; 10:1, 2010.
[2]. Wadhwa, S.D. and Higginbotham, E.J. Ethnic Differences in Glaucoma: Prevalence, Management and outcome. Curr. Opin. Ophthal.; 16, 2005, 101-106.
[3]. Girkin, C.A. POAG in African Americans. Int. Ophthalmol. Clin.; 44: 2004, 43-60.
[4]. Racette, L., Wilson, M.R., Zangwill, L.M. et al. POAG in Blacks: A review. Surv. Ophthalmol.; 48: 2003, 295-313.
[5]. Sommer, A., Tielsch, J.M., Katzm J., et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N. Engl. J. Med.; 325: 1991, 1412-7.

[1]. Ravindra GM, Shailaja GM, Anita AM. In vitro Screening of Cleome viscosa. Extract for anthelmintic activity. Pharmaceut.Bio.10: 2007; 766-768.
[2]. Nakatani, M., Huang, R.C., Okamura, H., Iwagawa, T., Tadera, K., 1998. Degrade
[3]. limonoids from Meliaazedarach. Phytochemistry 49, 1773-1776.Pomilio, A.B, Vitale, A.A, 1988.Métodos.
[4]. Mendhe BB. Nema U, Gupta P. and Gandhare BR, 2010. "Evaluation of Anthelmintic activity of leaf extracts of ButeaMonosperma" International Journal of Pharmaceutical Sciences and Research 1(3): p. 69-72.
[5]. Qureshi S. Md., Patel J., Giri C. I., Hasan S, Shaik M. and HamedMd,. "In vitro anthelmintic activity of root extract of TrapabispiniosaRoxb. Against Pheretimaposthuma and Ascardiagilli. Study of anthelmintic activity" International Journal ofPharma Science and Research 1 (9), 2010, p. 353-356.

[1]. Amlodipine: MedlinePlus Drug Information"www.nlm.nih.gov, Retrieved 2015-. [2]. Cash, Jill C.; Glass, Cheryl Anne, Family Practice Guidelines, Third Edition, 2014.
[3]. JP. Bounhoure, G. Bottineau andP.Lechat, Value of perindopril in the treatment of chronic congestive heart failure: multicentredouble-blind placebo-controlled study,ClinExpHypertens, 11(2), 1989, 575-586.
[4]. Indian Pharmacopoeia–2007, Govt. of India Ministry of Health and Family Welfare, The Indian Pharmacopoeia Commission, Ghaziabad, Vol 2 & 3, pp- 745-746, 1676-1677.
[5]. British Pharmacopoeia (BP) 2008 The Stationery Office. London, UK, Vol I, pp -37-138,1690-1692.

[1]. F.L. Westphal, L.C. Lima, R.A. Guimarães, R.F.S. Souza, S.B. Couto, S.R. Nakajima, Avaliação das alterações pleuropulmonares após a injeção de óleo de resina de copaíba, extrato aquoso de crajiru e polivinilpirrolidona iodado (PVPI) na pleura e parênquima pulmonar de ratos, Rev. Col. Bras. Cir, 34, 2007, 170-176.
[2]. F.A. Pieri, M.C. Mussi, M.A.S. Moreira, Óleo de copaíba (Copaifera sp.): histórico, extração, aplicações industriais e propriedades medicinais, Res. Bras. Pl. Med, 11, 2009, 465-472.
[3]. N.M. Gomes, C.M. Rezende, S.P. Fontes, M.E. Matheus, A.C. Pinto, P.D. Fernandes, Characterization of the antinociceptive and anti-inflammatory activities of fractions obtained from Copaifera multifuga Hayne, Journal of Ethnopharmacology, 128, 2010, 177-183.
[4]. V.F. Veiga Junior, L. Zunino, M.L. Patitucci, A.C. Pinto, J.B. Calixto, The inhibition of paw oedema formation caused by the oil of Copaifera multifuga Hayne and its fractions, Journal of Pharmacy and Pharmacology, 58, 2006, 1405-1410.
[5]. V.F. Veiga Junior, E.C. Rosas, M.V. Carvalho, M.G.M.O. Henriques, A.C. Pinto, Chemical composition and anti-inflamatory activity of copaíba oils from Copaifera cearensis Huber ex Ducke, Copaifera reticulata Ducke and Copaifera multifuga Hayne – a comparative study, Journal of Ethnopharmacology, 112, 2007, 248-254..

[1]. Roger K. Verbeeck&Flora T. Musuamba. Pharmacokinetics and dosage adjustment in patientswith renal dysfunction, Eur J Clin Pharmacol (2009) 65:757–773
[2]. Waknine Y. Kidney Disease Classification to Include Albuminuria. Medscape Medical News. Available at http://www.medscape.com/viewarticle/776940. December 31, 2012; [Accessed at: July 24, 2016].
[3]. [Guideline] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013. 3:1-150.
[4]. O'Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol. 2007 Oct. 18(10):2758-65. [Medline].
[5]. Roger K. Verbeeck& Flora T. Musuamba, Pharmacokinetics and dosage adjustment in patients with renal dysfunction, Eur J ClinPharmacol (2009) 65:757 – 773..

[1]. J. Hughes, G. Ayoko, S. Collett, and G. Golding, Rapid quantification of methamphetamine: Using attenuated total reflectance Fourier Transform Infrared Spectroscopy (ATR-FTIR) and Chemometrics, Plos One Journal., 8(7), 2013, 1-7.
[2]. U.S. Department of Justice, Drugs of Abuse (Washington, 1997).
[3]. O. Baran, Determination of Narcotic and Psychotropic Substances by Using Infrared Spectroscopy (A Thesis Submitted to the Graduate of Natural and Applied Sciences of Middle East Technical University, 2005).
[4]. P. Rakesh, P. Charmi, and K.S. Rajesh, Quantitative analytical applications of FTIR spectroscopy in pharmaceutical and allied areas, J. Adv. Pharm. Edu. & Res., 4(2), 2014, 145-157.
[5]. H. Tsuchihashi, M. Katagi, M. Nishikawa, M. Tatsuno, H. Nishioka, A. Nara, E. Nishio, and C. Petty, Determination of methamphetamine and its related compounds using Fourier Transform Raman Spectroscopy, Applied Spectroscopy, 51(12), 1997, 1796-1799.

[1]. Baron, E.J., L.R. Peterson and S.M. Finegold. 1994. Laboratory methods in basic mycology. In: Bailey & Scotti's 9th Edition .Diagnostic Microbiology. The C.V. Mosby Company. Pp 689-775.
[2]. Bansod, S, Rai M. Emerging of mycotic infection in patients infected with Mycobacterium tuberculosis,World Journal of Medical Sciences 2008; 3:74-80.
[3]. Cheesbrough, M. 1994. Mycology. In: Medical Laboratory Manual for Tropical Countries Tropical Health Technology/Butter Worth Heineman Ltd, ELBS Edition. 11: pp372-391.
[4]. Eggimann, P., J. Garbino and D. Pittet. 2003. Epidemiology of Candida species infections in critically ill non- immunosuppressed patients. Lancet Infectious. Diseases, 3(II): 685-702.
[5]. Ghafoor, M. 1967. Effect of the polysaccharide fraction of Candida albicans on the growth of Mycobacterium tuberculosis. Thesis. Jinnah Post Graduate Medical Centre, Karachi, Pakistan.

[1]. Arunima Karkun and Seema Varma, 2016. Study and survey of Fungal diversity of Borra caves situated in Andhra Pradesh, India. International Journal of Research in Ayurveda and Pharmacy 7 (2): 241-246.
[2]. Desikachary, T.V. 1959. Monograph on Cyanophyta, I.C.A.R. New Delhi.
[3]. Dobat, K., 1970, Conside´rations sur la ve´ge´tation cryptogamique des grottes du Jura Souabe (sud-ouest de l'Allemagne): Annales de Spe´le´ologie, v. 25, no. 4, p. 872–907.
[4]. Haraprasad Bairagya 2014. Environmental conditions of Borra cave, Visakhapatnam,India..
[5]. International Journal of Environment, Vol. 3 (2) 150-166. [6]. Hoffman, L. 1989. Algae of terrestrial habitats. The Botanical Review 55:77-105.

[1]. Dinis, M. J., Bezerra, R. M. F., Nunes, F., Dias, A. A., Guesdes, C. V., Ferreira, L. M. M., Cone, J. W., Marques, G. S. M., Barros, A. R. N. and Rodrigues, M. A. M. (2009). Modification of wheat straw lignin by solid state fermentation with white-rot fungi. Bioresource Technology, 100, 4829- 4835
[2]. Durand, A. (2003). Bioreactor designs for solid state fermentation. Biochemical Engineering Journal, 13, 113-125.
[3]. Holker, U. and Lens, J. (2005). Solid-state fermentation: are there any biotechnological advantages? Current Opinion in Microbiology, 8, 301-306
[4]. Koncsag, C. I. and Kirwan, K. (2010). Heat and mass transfer study during wheat straw solid substrate fermentation with P. ostreatus, Chemical Bulletin of "Politechnica" University of Timisoara, 55, 1-4
[5]. Mitchell, D. A., Krieger, N., Stuart, D. M. and Pandey, A. (2000). New developments in solid-state fermentation: II. Rational approaches to the design and scale-up of bioreactors. Process Biochemistry, 5, 1211-1225

[1]. Saijo K, Glass CK (2011). Microglial cell origin and phenotypes in health and disease. Nature Reviews Immunology, 11 (11): 775-87 . [2]. Zlokovic BV (2008). The blood brain barrier in health and chronic neurodegenerative disorders. Neuron ,57(2):178-201.
[3]. Lampron A, Elali A, Rivest S (2013). Innate Immunity in the CNS: Redefining the Relationship between the CNS and it's Environment. Neuron,24;78 (2):214-32.
[4]. Jacobs S, Doering LC (2010) Astrocytes Prevent Abnormal Neuronal Development in the Fragile X Mouse. The Journal of Neuroscience, 24;30(12):4508-14.
[5]. Akiyama H (2000). Inflammation and Alzheimer's Disease. Neurobiology of Aging, 21(3):383-421.

[1]. Al-Aali, K.Y. (2013). Prevalence of Vaginal Candidiasis among Pregnant Women Attending Al-Hada Military Hospital, Western Region, Taif, Saudi Arabia. International Journal of Science and Research. 4 (5): 1736 – 1743.
[2]. Anwar, K.P., Malik, A. and Subhan K.H. (2012). Profile of Candidiasis in HIV Infected Patients. Iranian Journal of Microbiology. 4 (4): 204 – 209.
[3]. Calderone R.A. (2001). Candida and candidiasis. Washington DC: ASM Press.
[4]. Costa, C.R.., Cohen, A.J., Fernandes O.F.L., Miranda, K.C., Passos, K.S. Souza A.K.H. and Silva R.R. (2016). Asymptomatic Oral Carriage of Candida species in HIV-infected Patients in the Highly Active Antiretroviral Therapy Era. Rev. Inst. Med. Trop. 48 : 257 – 261.
[5]. Durden F.M. and Elewsi, B. (1997). Fungal infections in HIV infected patients. Seminars in Cutaneous Medicine and Surgery. 16 (3): 200 – 212.